Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing therapeutics to improve the lives of patients with serious diseases. The Company currently has three product candidates in clinical development covering multiple potential indications. Cabiralizumab (FPA008) is an antibody that inhibits colony stimulating factor-1, or CSF1, receptor, or CSF1R, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis and in multiple cancers in combination with Bristol-Myers Squibb Company’s PD-1 immune checkpoint inhibitor, Opdivo (nivolumab). FPA144 is an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, that we are initially developing to treat patients with gastric (stomach) cancer and is in a Phase 1 clinical trial. FP-1039 is a fusion protein that “traps” and neutralizes cancer-promoting fibroblast growth factors, or FGFs, involved in cancer cell proliferation and new blood vessel formation that is in Phase 1b clinical development to treat patients with malignant pleural mesothelioma.

Show more

Employee Rating

2.3More
TypePublic
HQSouth San Francisco, US
Founded2001
Size (employees)216 (est)+11%
Websitefiveprime.com
Five Prime Therapeutics was founded in 2001 and is headquartered in South San Francisco, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Five Prime Therapeutics

Aron Knickerbocker

Aron Knickerbocker

CEO
Francis Sarena

Francis Sarena

Chief Strategy Officer and Secretary
Jeff Coon

Jeff Coon

Senior Vice President, Human Resources
Helen Collins

Helen Collins

Senior Vice President and Chief Medical Officer
Bryan Irving

Bryan Irving

Executive Vice President and Chief Scientific Officer
Nallakkan S. Arvindan

Nallakkan S. Arvindan

Senior Vice President, Strategic Technology Operations
Show more

Five Prime Therapeutics Office Locations

Five Prime Therapeutics has an office in South San Francisco
South San Francisco, (HQ)
2 Corporate Dr
Show all (1)
Report incorrect company information

Five Prime Therapeutics Financials and Metrics

Five Prime Therapeutics Revenue

USD

Net income (Q2, 2018)

(34.1m)

EBIT (Q2, 2018)

(35.6m)

Market capitalization (4-Dec-2018)

451.1m

Closing stock price (4-Dec-2018)

12.7

Cash (30-Jun-2018)

52.8m
Five Prime Therapeutics's current market capitalization is $451.1 m.
Annual
USDFY, 2013FY, 2015FY, 2016FY, 2017

General and administrative expense

10.4m22.6m35.8m40.0m

R&D expense

32.8m70.2m94.1m150.9m

Operating expense total

43.2m92.8m129.9m190.9m

EBIT

(29.4m)287.0m(99.2m)(151.4m)
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

General and administrative expense

2.6m3.3m3.0m3.4m4.6m5.2m8.6b8.1b9.1m10.5m9.4m9.7m10.5m9.8m

R&D expense

8.2m8.9m11.9m9.8m13.3m24.7m18.3b22.2b23.9m33.8m41.7m42.7m43.6m33.4m

Operating expense total

10.8m12.2m14.9m13.2m17.9m29.9m26.9b30.3b33.0m44.2m51.1m52.4m54.0m43.2m

EBIT

(7.3m)(8.7m)(9.9m)(7.1m)(11.6m)(24.1m)(20.4b)(21.1b)(26.4m)(34.1m)(43.3m)(44.1m)(21.5m)(35.6m)
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

8.2m15.3m150.0m7.7m59.8m

Accounts Receivable

Inventories

Current Assets

77.7m151.3m528.3m440.1m311.2m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(28.9m)(37.4m)249.6m(65.7m)(150.2m)

Depreciation and Amortization

1.7m1.6m1.7m1.7m2.5m

Inventories

Accounts Payable

(209.0k)701.0k798.0k(1.6m)1.9m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Net Income

(11.5m)(24.0m)(13.0b)(13.1b)(19.4b)(33.4b)(43.3b)

Accounts Payable

3.8m347.0k767.0k672.0k904.0k1.4m1.6m1.0m654.0k528.0k807.0k1.3m2.9m
USDY, 2018

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information

Five Prime Therapeutics Online and Social Media Presence

Embed Graph
Report incorrect company information

Five Prime Therapeutics News and Updates

Report incorrect company information

Five Prime Therapeutics Blogs

Five Prime Therapeutics and Zai Lab Dosed First Patient in Phase 3, Global Registrational Trial of Bemarituzumab in Front-Line Advanced Gastric and Gastroesophageal Junction Cancers

Phase 3 trial evaluating bemarituzumab plus mFOLFOX6 versus placebo plus mFOLFOX6 SOUTH SAN FRANCISCO, Calif. & SHANGHAI --(BUSINESS WIRE)--Oct. 1, 2018-- Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein

Five Prime Therapeutics to Present at Leerink Partners Roundtable Series: Rare Disease & Oncology

SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 26, 2018-- Five Prime Therapeutics, Inc . (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced that Aron Knickerbocker , Chief Executive Officer, will present at the

Five Prime Therapeutics Company Life and Culture

Report incorrect company information

Five Prime Therapeutics Frequently Asked Questions

  • When was Five Prime Therapeutics founded?

    Five Prime Therapeutics was founded in 2001.

  • Who are Five Prime Therapeutics key executives?

    Five Prime Therapeutics's key executives are Aron Knickerbocker, Francis Sarena and Jeff Coon.

  • How many employees does Five Prime Therapeutics have?

    Five Prime Therapeutics has 216 employees.

  • Who are Five Prime Therapeutics competitors?

    Competitors of Five Prime Therapeutics include Heat Biologics, Aeglea Biotherapeutics and Immune Design.

  • Where is Five Prime Therapeutics headquarters?

    Five Prime Therapeutics headquarters is located at 2 Corporate Dr, South San Francisco.

  • Where are Five Prime Therapeutics offices?

    Five Prime Therapeutics has an office in South San Francisco.

  • How many offices does Five Prime Therapeutics have?

    Five Prime Therapeutics has 1 office.